# Mipletamig PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mipletamig

> Mipletamig, sponsored by Aptevo Therapeutics Inc. (APVO): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | mipletamig |
| Codes |  |
| Sponsor | Aptevo Therapeutics Inc. (APVO) https://sec-api.dev/companies/apvo/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0000950170-25-020467): "The decrease was primarily due to lower preclinical spending and lower mipletamig trial costs as we concluded our Phase 1b dose expansion study and initiated the Phase 1b/2 dose optimization study in August of 2024." https://www.sec.gov/Archives/edgar/data/1671584/000095017025020467/apvo-20241231.htm

### November 20, 2024: trial start

- Status: completed. Date confidence: exact.
- First seen 2024-11-20, last confirmed 2024-11-22.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-129971): "The Company announced an initial efficacy response earlier this week where the first patient dosed experienced a 90% reduction in leukemic blasts within 30 days of treatment initiation, continuing the efficacy trend seen in prior mipletamig clinical studies." https://www.sec.gov/Archives/edgar/data/1671584/000095017024129971/apvo-ex99_1.htm
- SEC Form 8-K (accession 0000950170-24-129018): "On November 20, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") announced that the first patient dosed in Aptevo's ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, supporting the continued overall efficacy trend seen in prior mipletamig AML studies." https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-20241120.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mipletamig.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mipletamig PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mipletamig

```bibtex
@misc{secapidev_pdufa_mipletamig_20261116,
  title        = {Mipletamig PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mipletamig}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mipletamig_20261116","title":"Mipletamig PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mipletamig","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
